Drug Trial Radar · NCT05929079
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,152
Actual
Start
Jul 11, 2023
Primary completion
Jun 16, 2026
Study completion Jun 16, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Conditions
- Type 2 Diabetes
- Obesity
- Overweight
- Obstructive Sleep Apnea
Interventions
RetatrutideDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Baseline, Week 80
- Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 SubsetTime frame: Baseline, Week 80
Locations
98 sites in 8 countries. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
Cullman Clinical Trials
Cullman, Alabama
Preferred Research Partners
Little Rock, Arkansas
Core Healthcare Group
Cerritos, California
Velocity Clinical Research, Westlake
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Chase Medical Research, LLC
Waterbury, Connecticut
Excel Medical Clinical Trials
Boca Raton, Florida
Teradan Clinical Trials, LLC
Brandon, Florida
Fleming Island Center for Clinical Research
Fleming Island, Florida
Therafirst Medical Center
Fort Lauderdale, Florida
Clinical Site Partners LLC, dba Flourish Research
Miami, Florida
Quantum Clinical Trials
Miami Beach, Florida
Renstar Medical Research
Ocala, Florida
Clinical Research Center of Florida
Pompano Beach, Florida
Palm Beach Research Center
West Palm Beach, Florida
Clinical Site Partners, LLC dba Flourish Research
Winter Park, Florida
NeuroTrials Research Inc
Atlanta, Georgia
Centricity Research Rincon Pulmonology
Rincon, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Brengle Family Medicine
Indianapolis, Indiana
MedVadis Research Corporation
Waltham, Massachusetts
StudyMetrix Research
City of Saint Peters, Missouri
Las Vegas Medical Research
Las Vegas, Nevada
Mid Hudson Medical Research
New Windsor, New York
Monroe Biomedical Research
Monroe, North Carolina
Carteret Medical Group
Morehead City, North Carolina
Lillestol Research
Fargo, North Dakota
CTI Clinical Research Center
Cincinnati, Ohio
Intrepid Research
Cincinnati, Ohio
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
Pittsburgh, Pennsylvania
Preferred Primary Care Physicians
Uniontown, Pennsylvania
Tribe Clinical Research, LLC
Greenville, South Carolina
Trial Management Associates
Myrtle Beach, South Carolina
Tribe Clinical Research - Spartanburg
Spartanburg, South Carolina
FutureSearch Trials of Neurology
Austin, Texas
Velocity Clinical Research, Dallas
Dallas, Texas
Advanced Research Institute
Ogden, Utah
Northwest Clinical Research Center
Bellevue, Washington
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.